$HLN

Haleon has secured better shelf positions at Walmart and Target, including eye-level space, by offering lower prices, promotions, and exclusive products. The company's US consumer-health market share increased from 11.4% to 12% between February and August, according to NielsenIQ data. This strategy aims to attract price-conscious shoppers as they focus on essential products.

Haleon's US market share in healthcare rose to 12% by August, with 21% of Q2 sales from promotions. Bernstein estimates P&G held 10.8% in July. Eye-level shelf space may boost sales but could pressure margins if promotions end.

Haleon, the maker of Sensodyne, secured better shelf placement at Walmart and Target by offering lower prices, promotions, and exclusivity. According to NielsenIQ, Haleon's U.S. market share rose to 12% in August from 11.4% in February. The company's strategy includes placing products at eye level and using promotions to drive sales. Walmart and Target declined to comment.

Haleon, a consumer health company, is investing £175m (US$235m) to build its first manufacturing site in Madhya Pradesh, India, aiming to reach one billion more consumers by 2030. The plant, set to open in January 2028, will create 500 permanent jobs and boost India's local economy. Haleon is also focusing on simplifying its supply chain and implementing automation, having installed 2,500 robotic equipment in 20 months.

Jefferies raised its price target for Haleon to 410p from 400p, citing a 70 basis point margin beat in H1. Haleon reported 3.1% organic sales growth in Q2, with Oral Health and Pain Relief segments performing well. Shares rose 0.28% to 364.10p. Jefferies expects 5%+ growth in H2 to meet guidance.

Haleon's H1 2026 operating margin expanded 160 bps to 24.3%, driven by cost savings, but organic sales growth was 2.6%. Jefferies notes strong execution but questions growth investment. Q2 sales grew 3.1%, with varied performance across segments. Jefferies raised its price target to 410 pence, citing 13% upside.

Haleon (HLN) announced a $2.0B cash tender offer for its 3.375% Fixed Rate Senior Notes due March 2027. The offer targets $1.999B in outstanding notes, with details available via the London Stock Exchange and the UK Financial Conduct Authority.

Haleon plc (HLN) announced the pricing terms, expiration, and results of its cash tender offer for $1.999 billion 3.375% Fixed Rate Senior Notes due 2027. The offer expired on 18 August 2026, with settlement expected on 21 August 2026, subject to conditions, including the successful issuance of new notes.

According to Reuters, Haleon has launched and priced a three-tranche, $2 billion fixed-rate US dollar bond offering. The company set the terms across multiple maturities, with proceeds intended for general corporate purposes and refinancing needs. The deal provides a new funding source and may affect Haleon’s capital structure and debt costs.

Haleon priced a $2.0 billion three-tranche bond via Haleon US Capital LLC, settling Aug. 21. Tranches: $600m due 2029 at 4.625%, $600m due 2031 at 4.875%, and $800m due 2036 at 5.375%. Haleon plc guarantees principal and interest. Net proceeds will fund repurchase of $1.999bn 3.375% notes due Mar 2027 and remaining for general corporate purposes, according to the company.